Treatment for Substance Use Disorder With Co-Occurring Mental Illness
Open accessThe DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.
Abstract
Substance use disorder is a highly prevalent condition, leading to significant morbidity, mortality, and burden on the health care system. Substance use disorders are overrepresented among individuals with a mental illness. The term "dual diagnosis" was introduced by the World Health Organization in the mid-1990s and refers to the co-occurrence of a substance use disorder with mental illness-a more recently used term is "co-occurring disorders." In the past decade, substantial progress has been made toward expanding psychotherapeutic and pharmacotherapeutic treatments for treating co-occurring disorders. Yet management remains a challenge among clinicians and has been a source of confusion and considerable controversy. This review describes the epidemiology and treatment of co-occurring disorders, with a focus on major depressive disorder, anxiety disorders, and attention-deficit hyperactivity disorder. Substance use may make diagnosis of the underlying psychiatric condition difficult, and a period of abstinence may be necessary. Findings from efficacy studies of medications used to treat co-occurring disorders are reviewed, as are results of preliminary studies of newer treatments, such as topiramate, ketamine, noninvasive brain stimulation, and deep brain stimulation. Treatment recommendations that combine medications and psychosocial interventions are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Posttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Bardo, M. T., & Hammer, R. P. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90226-e · Cited by 3,219
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Research works printed but not linked: 6
- Centers for Disease Control and Prevention (CDC), 2010, Morb Mortal Wkly Rep, 59, 1229
- Hasin DS, 1998, Drug Alcohol Depend, 39, 197
- 10.1111/j.1530-0277.2000.tb04648.x · doi:10.1111/j.1530-0277.2000.tb04648.x · Paper page
- 10.1037/0893-164X.7.4.211 · DOI · Paper page
- Niciu MJ, 2014, Int J Neuropsychopharmacol, 18, pyu039
- Rapinesi C, 2013, Prim Care Companion CNS Disord, 15, PCC.12m01438
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“Pharmacological interventions play a pivotal role in the treatment of SUDs and psychiatric conditions [22].”
BackgroundLevitt, E. E., Syan, S. K., Sousa, S., Costello, M. J., Rush, B., Samokhvalov, A. V., McCabe, R. E., Kelly, J., & MacKillop, J. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106649 · Cited by 35
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Chiappini, S., Sampogna, G., Ventriglio, A., Menculini, G., Ricci, V., Pettorruso, M., Volpe, U., & Martinotti, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2470973 · Cited by 24
Icick, R., Moggi, F., Slobodin, O., Dom, G., Matthys, F., van den Brink, W., LEVIN, F. R., Blankers, M., Kaye, S. S., Demetrovics, Z., et al. (2020) · European Addiction Research · doi:10.1159/000508546 · Cited by 28
Self-citationBarriers to retention in substance use treatment: Validation of a new, theory-based scale
Zemore, S. E., Ware, O. D., Gilbert, P. A., & Pinedo, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108422 · Cited by 21
Metadata
- Authors
- Iqbal, M. N., Levin, C. J., & Levin, F. R.
- Affiliations
- New York State Psychiatric Institute (US)
- Venue
- Focus
- Published
- 2019-04
- Volume
- 17
- Issue
- 2
- Pages
- 88-97
- ISSN
- 1541-4094 (ISSN-L)
- 1541-4108
- PMC
- PMC6526999
- OpenAlex
- W2938661501
- Cited by
- 66
- References
- 169
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 14 · 2023: 10 · 2022: 5 · 2021: 11 · 2020: 4 · 2019: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- FOCUS The Journal of Lifelong Learning in Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA029647, T32DA007294)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- substance use disorders, co-occurring disorders, dual diagnosis, major depressive disorder, anxiety disorders, attention deficit hyperactivity disorder, pharmacotherapy, psychotherapy, topiramate, ketamine, non-invasive brain stimulation, deep brain stimulation, abstinence, comorbidities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment for Substance Use Disorder With Co-Occurring Mental Illness. https://app.cochat.ai/papers/10.1176/appi.focus.20180042
- The paper
- Iqbal, M. N., Levin, C. J., & Levin, F. R. (2019). Treatment for Substance Use Disorder With Co-Occurring Mental Illness. Focus. https://doi.org/10.1176/appi.focus.20180042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.